Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Essence's revenue for the
three
months ended in Jun. 2026 was $0.80 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $2.91 Mil.
Bio Essence's Revenue per Share for the
three
months ended in Jun. 2026 was $0.02.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.07.
During the past 12 months, the average Revenue per Share Growth Rate of Bio Essence was 337.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 38.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 7 years, Bio Essence's highest 3-Year average Revenue per Share Growth Rate was 38.10% per year. The lowest was -30.70% per year. And the median was -8.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Bio Essence Revenue Related Terms
Bio Essence Revenue Historical Data
* Premium members only.
The historical data trend for Bio Essence's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bio Essence's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Essence Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bio Essence's Revenue distribution charts can be found below:
* The bar in red indicates where Bio Essence's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Essence (BIOE) has a Revenue of $2.91 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Bio Essence and its competitors.
Is Bio Essence's Revenue too high?
Bio Essence's current Revenue is $2.91 Mil. Overall, Bio Essence has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Bio Essence's Revenue compare to INM and SNOA?
Bio Essence's Revenue of $2.91 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Bio Essence and its competitors. Bio Essence's current Revenue is $2.91 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Essence stock overvalued right now?
Bio Essence (BIOE) has a current Revenue of $2.91 Mil. The current Revenue is $2.91 Mil. Bio Essence's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Bio Essence (BIOE), the current Revenue is $2.91 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Essence Corp is an herbal health, diet, and nutrition company. The Company's mission is to provide herbal health, diet, and vitamin nutritional supplements. The primary focus of BEP was producing products for BEH and McBE, along with providing original equipment manufacturing and private label services to other companies. BEH targeted and developed traditional Chinese medicines (TCM) in the form of single herbs, granules, pills, and tablets. It also offered specially formulated dietary supplements and medical food. The Company operates in one business and industry segment: the manufacture / OEM and sale of health supplement products. The group's products are RED Yeast Rice Plus, Regenva, MediDrink, and Nufargo.
35GF Score
Get the complete analysis for BIOE
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIOE has been successfully added to your 
